Home › Peripheral Nerve Disorders › NCT03150511
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
Tesamorelin Therapy to Enhance Axonal Regeneration, Minimize Muscle Atrophy, and Improve Functional Outcomes Following Peripheral Nerve Injury
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Ulnar nerve laceration at the wrist, repaired primarily Exclusion Criteria: * Certain cancers (active or in the past) * Uncontrolled diabetes or hypertension * Certain pituitary problems * Oral contraceptives * Pregnancy * Drug or alcohol dependence * Psychosocial issues that would limit participation and compliance
About the study
The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries. The investigators hypothesize that treatment with tesamorelin will result in faster and more substantial recovery of motor and sensory function following surgical repair of injured peripheral nerves. Patients with upper extremity nerve injuries will be randomly assigned to receive either tesamorelin treatment or no treatment. Assessments for nerve regeneration, muscle function, and sensation will be conducted every three months for a total of 12 months. Outcomes in patients receiving tesamorelin will be compared to those in the untreated group to determine the effectiveness of tesamorelin as a therapeutic intervention for nerve injuries.
What is being tested
- Tesamorelin 2 Milligrams (MG) (drug)
Sponsor: Johns Hopkins University · Participants: 36 · Started: Jun 1, 2018
Contact the study team
- Sami Tuffaha, MD · Phone: 410-614-4333
Official record on ClinicalTrials.gov — NCT03150511
Locations in the U.S.
| Maryland | Sami Tuffaha, Baltimore |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.